Системные антимикотики: состояние и перспективы | КМАХ

Системные антимикотики: состояние и перспективы

Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(1):73-80

​ Веселов А.В.
антимикотики противогрибковая терапия микозы инвазивные грибковые инфекции
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(1):73-80

Аннотация

Инвазивные грибковые инфекции — растущая проблема современной медицины. Распространённость инвазивных грибковых инфекций значительно выросла за последние несколько десятилетий параллельно с увеличением популяции иммунокомпрометированных пациентов. Количество доступных и разрешённых к применению системных антимикотиков на сегодняшний день недостаточно, а прогресс в создании новых препаратов не в полной мере соответствует темпам роста распространённости инвазивных микозов. В статье в краткой форме изложены ключевые моменты применительно к существующим и ожидающимся в скором будущем системным антимикотикам, которые могут помочь практикующему врачу сориентироваться с выбором препаратов в той или иной клинической ситуации.

  • 1. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2:73-85.
  • 2. Nucci M., Marr K.A. Emerging fungal diseases. Clin Infect Dis 2005; 41:521-6.
  • 3. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
  • 4. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
  • 5. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective Multicenter surveillance program. Med Mycol 2005; 43(Suppl 1):S49-58.
  • 6. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49(Suppl 1):7-10.
  • 7. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006; 27(Suppl 1):12-6.
  • 8. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49:31-6.
  • 9. Ng A.W., Wasan K.M., Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003; 6:67-83.
  • 10. Krupova Y., Mistrik M., Bojtarova E., et al. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001; 9:209-10.
  • 11. Rios A., Rosenblum M., Crofoot G., et al. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis 1993; 168:253-4.
  • 12. Maertens J., Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56(Suppl 1): i33-i38.
  • 13. Prentice A.G., Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56(Suppl 1):i17-i22.
  • 14. Charlier C., Hart E., Lefort A., et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57:384- 410.
  • 15. Pfaller M.A., Diekema D.J., Rinaldi M.G., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848-59.
  • 16. Herbrecht R., Denning D.W., Patterson T.F., et al. Vorico­nazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
  • 17. Keady S., Thacker M. Voriconazole in the treatment of invasive fungal infections. Intensive Crit Care Nurs 2005; 21:370-3.
  • 18. Kulemann V., Bauer M., Graninger W., Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005; 75:165-78.
  • 19. Hof H. A new, broad-spectrum azole antifungal: posaconazole – mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49(Suppl 1):2-6.
  • 20. Notheis G., Tarani L., Costantino F., et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006; 49(Suppl 1):37-41.
  • 21. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
  • 22. Aperis G., Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15:579-602.
  • 23. Available from: http://clinicaltrials.gov/ .
  • 24. Letscher-Bru V., Herbrecht R. Caspofungin: the first repre­sentative of a new antifungal class. J Antimicrob Chemother 2003; 51:513-21.
  • 25. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-35.
  • 26. Mora-Duarte J., Betts R., Rotstein C., et al. Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non neutropenic patients: a multicentre randomized double-blind study. Clin Microbiol Infect 2002; 8:33-4.
  • 27. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
  • 28. Groll A.H., Stergiopoulou T., Roilides E., Walsh T.J. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005; 14:489-509.
  • 29. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-61.
  • 30. Clemons K.V., Stevens D.A. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006; 44:69-73.
  • 31. Cohen-Wolkowiez M., Benjamin D.K. Jr., Steinbach W.J., Smith P.B. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today (Barc) 2006; 42:533-44.
  • 32. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-5.
  • 33. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-4.
  • 34. Available from: www.indevus.com.
  • 35. Ghannoum MA, Isham N. Determination of minimum inhibitory concentration of Aminocandin against yeasts and filamentous fungi. J Clin Microbiol 2006; 44: 4342-4.
  • 36. Vermes A., Guchelaar H.-J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46:171-9.
  • 37. Rex J.H., Pfaller M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982-9.
  • 38. Hosoe T., Fukushima K., Takizawa K., et al. A new antifungal macrolide, eushearilide, isolated from Eupenicillium shearii. J Antibiot (Tokyo) 2006; 59:597-600.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились